Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

VAMPIRE

Financiado

Cerrado

Vascular antibody mediated pharmaceutically induced tumour resection

The most significant advance in cancer therapeutics in recent years has been the introduction of monoclonal antibodies into widespread clinical usage. A consequence of this rapid emergence of antibodies as therapeutics is a lack o... ver más

31/08/2017

UoB

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

THE UNIVERSITY OF BIRMINGHAM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-08-31 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UoB

0.00€ | Lider

SOM

8.80K€ | Participante

Proyectos interesantes

CARDIMMUN

Medical Technol...

Data Science

8M€ Cerrado

TACT

Medical Technol...

Data Science

3M€ Cerrado

IMMUTRAIN

Medical Technol...

Data Science

4M€ Cerrado

PID2019-105404RB-I00

Medical Technol...

Data Science

127K€ Cerrado

SUMMIT

Medical Technol...

Data Science

2M€ Cerrado

PRe-ART-2T

Medical Technol...

Data Science

800K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

THE UNIVERSITY OF BIRMINGHAM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The most significant advance in cancer therapeutics in recent years has been the introduction of monoclonal antibodies into widespread clinical usage. A consequence of this rapid emergence of antibodies as therapeutics is a lack of trained scientists within the EU with the requisite skills to enable antibody development at a globally competitive pace. The University of Birmingham (UoB) together with the SME SomantiX (SOM) aims to address this need by training the next generation of scientists with the appropriate skills. Together with seven associated partners, we have created an intersectorial EID proposal titled Vascular-Antibody Mediated Pharmaceutically Induced tumour REsection or VAMPIRE. The primary aim of the proposal is to train 5 early stage researchers while conducting an internationally competitive oncology research project. VAMPIRE will provide training across a wide range of disciplines involved in the production of antibodies and in their evaluation as therapeutics in animal models of cancer. Training will be provided through an integrated partnership involving all of the partners in the consortium ensuring interdisciplinary and intersectoral experience for the ESRs. The antibodies that we aim to develop will target markers of the tumour vasculature that we have identified previously, including CLEC14A. The commercial partner SOM is a Dutch SME specialized in the development of tumour vascular targeting agents. The findings of this project will be of interest to cancer research and the wider public community. Intellectual property generated by the project is envisioned to be licensed to SOM. Pre-clinical development of the antibodies is envisioned to be carried out via strategic alliances with academic partners and other small biotechnology companies. We view pharmaceutical companies as future business and product development partners in clinical phases of antibody testing.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores